<DOC>
	<DOCNO>NCT01038752</DOCNO>
	<brief_summary>The purpose study evaluate benefit add suramin non-cytotoxic dose carboplatin docetaxel regimen treatment chemo-naïve patient non-small cell lung cancer .</brief_summary>
	<brief_title>Evaluation Non-cytotoxic Suramin Chemosensitizer Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The primary objective determine progression free survival patient stage III B malignant pleural effusion Stage IV NSCLC treat docetaxel carboplatin without suramin . The secondary objective compare median overall survival rate , compare overall response rate patient arm , assess toxicity suramin docetaxel carboplatin , determine whether pre-treatment bFGF level correlate survival , determine whether survival benefit suramin associate M phase entry peripheral blood lymphocyte , determine whether add suramin docetaxel carboplatin produce great survival benefit African-American patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<criteria>Histologically cytologically proven onsmall cell lung cancer ( NSCLC ) , include squamous cell carcinoma . Newlydiagnosed stage IIIB malignant pleural effusion , stage IV recurrent disease . Known central nervous system metastases patient asymptomatic complete whole brain stereotactic radiation least 2 week prior surgery least 4 week prior start treatment protocol . Must dexamethasone time start treatment . Must complete radiotherapy least two week prior registration . Prior radiation therapy eligible patient measurable lesion irradiate . Must measurable disease , define least one lesion accurately measure least one dimension ( RECIST criterion ) . Lesions consider measurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion situate previously irradiate area ECOG performance status 01 . Life expectancy ≥ 3 month . Adequate bone marrow function , absolute neutrophil count ≥1,500/mm3 , hemoglobin ≥9.9 gm/dl , platelet count ≥100,000/mm3 . Adequate liver function define bilirubin ≤ 1x upper level institutional normal ( ULIN ) . AST ALT Alkaline Phosphatase must within range allow eligibility . In determine eligibility abnormal two value ( AST ALT ) use . See protocol . Must adequate renal function define serum creatinine ≤ 2.0 mg/dl calculate creatinine clearance ≥ 60 ml/min patient creatinine level 2.0 mg/dl . Must recover uncontrolled intercurrent illness , include ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . Use adequate contraception ( hormonal barrier method birth control ) duration study participation continue least three month complete treatment . Nonpregnant status determine woman childbearing potential . Age &gt; 18 . Patients must give write informed consent . Entry study open men woman racial ethnic subgroup . The goal accrue minimum 44 patient AfricanAmerican ancestry maximum 120 nonAfricanAmerican patient . Classification patient race ancestry base patient 's selfidentification consent form clinical trial . History severe hypersensitivity reaction Docetaxel drug formulate polysorbate 80 . Grade 3 4 neuropathy . Women pregnant breastfeeding . Prior chemotherapy biologic therapy ( e.g. , erlotinib ) NSCLC include neoadjuvant adjuvant chemotherapy . Currently active second malignancy nonmelanoma skin cancer . Currently active malignancy include prior malignancy treat therapy consider less 30 % risk relapse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>suramin</keyword>
	<keyword>lung cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>